|Articles|November 25, 2020

COVID-19 Survivors Improve with Home Health Care

Author(s)Killian Meara

Recent study shows COVID-19 survivors health improves with support of Home Health Care.

A recent Pennsylvania School of Nursing study has shown that survivors of coronavirus disease 2019 (COVID-19) significantly improve with the aid of home health care (HHC) workers. Data uncovered through the study indicates increasing home health care greatly improves the recovery time of patients who receive it.

The study, published in Annals of Internal Medicine, received data from more than 1,400 patients who were admitted to home health care after recovering from COVID-19 and being discharged from a hospital. The average age of the cohort was 67 years old, with common comorbid conditions like hypertension and diabetes. In most cases, the patients had an average of 6 functional deficits, mostly to do with activities of daily living (ADL).

One month following the discharge from HHC, a majority of the patients showed improvements in cognition, anxiety and dyspnea. It was also shown that with the assistance of home health care, such as physical therapy and skilled nursing, 94% of the patients achieved statistically significant improvements in both functional outcomes and symptom burden. The average functional deficit dropped from 6 to 1, showing a notable improvement in functional gains.

"Our findings suggest that acute care providers might carefully consider which COVID-19 survivors would benefit from home health care after hospitalization," Kathryn H. Bowles, PhD, RN, lead author on the study said. "A decision support tool to identify general hospitalized patients for home health care referral may be helpful."

The study recommends that to prepare for postacute care surges due to COVID-19, an expansion of HHC use should be made to provide skilled nursing and rehabilitative services in the home. This will help to prevent the transmission to other patients, which can occur in inpatient facilities.

“The positive outcomes profiled in this study suggest the value and importance of discharging vulnerable COVID-19 survivors to skilled HHC to support their recovery,” Bowles writes. “Increasing referrals to HHC has the potential to provide support and achieve improved recovery for perhaps many more patients.”


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.